BioSpace News Archive

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that three abstracts highlighting data and information from the clinical development program evaluating the intermittent dosing of zandelisib, an investigational phosphatidylinositol 3-kinase delta inhibitor for the treatment of B-cell malignancies, will be presented at the upcoming American Society of Hematology 2022 Annual Meeting to be held December 10 – 13, 2022.

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies that target signal regulatory proteins (SIRP), announced today that the company will present three posters related to the company’s lead drug candidate, ELA026, at the American Society of Hematology (ASH) annual meeting being held in New Orleans, Louisiana, December 10-13, 2022.

Electromed, Inc., a leader in innovative airway clearance technologies, announced that management is scheduled to participate in two upcoming investor conference during the month of November 2022: Sidoti & Company November Micro-Cap Virtual Conference on November 9-10, 2022.

Asher Biotherapeutics, Inc. (Asher Bio) today announced that it will present preclinical data showing that cis-targeted IL-2 or IL-21 cytokine fusion molecules selectively augment CAR-Ts in vitro and enhance in vivo anti-tumor activity and survival at the 64th American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, December 10-13, 2022.

Oculis S.A. announced significant expansion of its Scientific Advisory Board with the appointments of six world-leading medical experts, Christophe Baudouin, M.D., PeterK.

Sanara MedTech Inc. and InfuSystem Holdings, Inc. announced the establishment of a partnership, SI Wound Care, LLC, focused on delivering a complete wound care solution targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results on Wednesday, November 9, 2022.

Affimed N.V. (Nasdaq: AFMD) (“Affimed”), and Artiva Biotherapeutics Inc. (“Artiva”), both immuno-oncology companies focused on developing and commercializing therapies utilizing the innate immune system, today announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed’s Innate Cell Engager (ICE®) AFM13 and Artiva’s cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101.

Reaction Biology Corporation (“Reaction”) and Vyant Bio, Inc. (“Vyant Bio”) (Nasdaq: VYNT) today announced that the companies have closed on a definitive agreement for Reaction to acquire Vyant Bio’s subsidiary vivoPharm LLC, located in Hershey, Pennsylvania.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA.